Novaliq
Novaliq GmbH , a Germany based specialty pharmaceutical company, transforms poorly soluble drugs into effective therapeutics for ophthalmology and derma, using a novel and disruptive drug delivery platform. Novaliq’s most advanced product is NovaTears® with CE-marking based on Novaliq’s proprietary EyeSol® technology and is marketed under the brand name EvoTears® in Europe.
Participant:
Bernhard Günther
Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in the field of ocular biopharmaceutics and medical devices.